Poor Sleep Quality Predicts Shorter Survival in Metastatic Breast Cancer Patients

Stanford University conducted a comprehensive study examining how sleep disruption and circadian rhythm dysfunction affect survival in women with metastatic breast cancer. The research was motivated by emerging evidence that shift work, poor sleep, and disrupted hormone cycles increase cancer risk and accelerate tumor growth.

The trial enrolled 141 participants, including 105 women aged 45-75 with metastatic or recurrent breast cancer and 20 healthy controls. Participants underwent extensive monitoring including two weeks of at-home sleep tracking with Actiwatch devices, EEG sleep monitoring, and 28 hours of continuous blood sampling to measure circadian hormone patterns.

Researchers measured cortisol, ACTH, and melatonin rhythms alongside immune function markers including natural killer cell activity and IL-6 levels. The study also assessed psychosocial factors like pain, depression, anxiety, and emotional support that might influence sleep quality.

The primary objectives were to determine whether women with metastatic breast cancer have disrupted circadian rhythms compared to healthy controls, and whether poor sleep quality predicts shorter survival times. Researchers hypothesized that sleep disruption would correlate with abnormal hormone patterns and compromised immune function.

This completed study provides crucial insights into the relationship between sleep, circadian biology, and cancer progression. The findings have significant implications for longevity and health optimization, potentially informing sleep management interventions that could improve cancer outcomes and extend survival in patients with metastatic disease.